# SHARED SOLUTIONS® PROGRAM SERVICES REFERRAL FORM AND RX



TO ENROLL YOUR PATIENTS PLEASE FAX THIS FORM TO: 1800643-0031

PATIENT INFORMATION						
LAST NAME	FIRST NAME		BIRTHDAY (YYYY/MM/DD)		SEX	
HOME ADDRESS		CITY	·	PROVINCE	POSTAL CODE	
PHONE #1 (MOBILE)	10H9	NE #2 (ALTERNATE) _		EMAIL		
PATIENT CONTACT PREFERENC	ce 🗌 mobile 🔲 alternat	E EMAIL	☐ DIRECT MAIL	SMS PREFERRED TIM	E AM PM	
PATIENT HAS PRIVATE INSURAN	NCE YES NO		DON'T KNOW	INSURANCE COMPANY_		
CLINICAL ASSESSMENT						
DIAGNOSIS RRMS		F	PREVIOUS MS THERA	APY		
	_ TEST DATE					
# OF RELAPSES IN THE LAST 2						
PRESCRIPTION	4 MONTHS					
PATIENT WAS GIVEN Rx	COPAXONE <b>40 MG/ML</b>	THREE TIMES- A-VA/EE	K DINI: 02456915		MG/ML ONCE-DAILY	DIN: 02245610
	DISPENSE 12 SYRINGES/B				INGES/BOX REFILL # _	
PATIENT CONSENT						
ITS PRIVACY POLICY, WHICH I PERSONAL INFORMATION OU I CONSENT TO BEING CONTA IN THE SHARED SOLUTIONS®,	ND AGREE TO THE COLLECTION HAVE HAD AN OPPORTUNITY TO JITSIDE CANADA, INCLUDING WI CTED BY SHARED SOLUTIONS® N PROVIDE SHARED SOLUTIONS®	REVIEW AND WHI THIN THE EUROPEAI VIA ELECTRONIC CO SERVICES, AND TO I	CH IS ATTACHED HEIN UNION, ISRAEL, COMMUNICATION (I.E. PROVIDE NOTIFICAT	RETO. I EXPRESSLY CONSENT TO OR THE USA, IN ACCORDANCE ,, BY EMAIL AND TEXT MESSAG IONS AND REMINDERS.	O THE SECURE STORAC WITH THE ATTACHED F E) TO INFORM ME ABC	GE OF MY PRIVACY POLICY.
WRITTEN CONSENT (YYYY	//MM/DD)		PATIENT SIGNATUR	E		
PHYSICIAN INFORMATION	ON AND AUTHORIZATION					
PHARMACY CHOSEN BY THE A	IONS® TO BE MY DESIGNATED . ABOVE NAMED PATIENT. THIS ORI HE ONLY PHARMACY TO RECEIVI	GINAL PRESCRIPTION	N CONSTITUTES A LE	GAL PRESCRIPTION FOR THE PA	TIENT FOR COPAXONE	
LAST NAME	FIRST NAME			LICENSE NUMBER		
WORK PHONE	FAX					
PHYSICIAN EMAIL	SIGNATU	IRE		CLINIC STAMP OR ADDI	RESS	
DATE (YYYY/MM/DD)						
PLEASE SEND REPORT ON	I PATIENT'S INJECTION TRAI	NING TO MD	NURSE			
LAST NAME	FIRST NAME					
EAV						

#### **COPAXONE® IS INDICATED FOR:**

20 MG/ML ONCE-DAILY: TREATMENT OF AMBULATORY PATIENTS WITH RELAPSING REMITTING MULTIPLE SCLEROSIS (RRMS), INCLUDING PATIENTS WHO HAVE EXPERIENCED A SINGLE DEMYELINATING EVENT AND HAVE LESIONS TYPICAL OF MULTIPLE SCLEROSIS ON BRAIN MRI TO DECREASE THE FREQUENCY OF CLINICAL EXACERBATIONS AND TO REDUCE THE NUMBER AND VOLUME OF ACTIVE BRAIN LESIONS IDENTIFIED ON MAGNETIC RESONANCE IMAGING (MRI) SCANS.

40 MG/ML THREE TIMES-A-WEEK: TREATMENT OF AMBULATORY PATIENTS WITH RELAPSING REMITTING MULTIPLE SCLEROSIS (RRMS) TO DECREASE THE FREQUENCY OF CLINICAL EXACERBATIONS AND TO REDUCE THE NUMBER AND VOLUME OF ACTIVE BRAIN LESIONS IDENTIFIED ON MAGNETIC RESONANCE IMAGING (MRI) SCANS.

## **FOR MORE INFORMATION:**

CONSULT THE PRODUCT MONOGRAPH AT HTTPS://WWW.TEVACANADA.COM/GLOBALASSETS/CANADA-SCS-FILES---GLOBAL/OUR-PRODUCTS-PDFS/0221 TCI COPAXONE\_PM\_EN.PDF FOR CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, ADVERSE REACTIONS, INTERACTIONS, DOSING, AND CONDITIONS OF CLINICAL USE. THE PRODUCT MONOGRAPH IS ALSO AVAILABLE BY CALLING US AT 1 800 283-0034.





## SHARED SOLUTIONS® PRIVACY POLICY

Shared Solutions® respects your privacy and is strongly committed to protecting your personal information. This privacy policy explains the information we may collect and how we use and safeguard that information. If you have any questions, or if you would like more information about the manner in which we or our authorized service providers treat your personal information, or to access your personal information in our records, do not hesitate to contact us using the information provided below.

## Why we ask you for personal information

In order for Shared Solutions® to offer you the services you require, we may request that you provide us with your personal information, including personal health information, or we may obtain personal information from your referring physician, pharmacist, insurance company, public payer or any other healthcare professional or payer that may possess the requisite information. We will not access, collect, use, or disclose any of your personal information unless you have provided your consent. We will only ask for the personal information necessary to serve you, to comply with our pharmacovigilance commitments and obligations (which may apply even after you leave the Shared Solutions® Patient Support Program), and to research, develop, and improve our products and services. Some of the services provided by Shared Solutions® include:

- providing you with personalized services to meet your specific needs;
- determining the suitability of our services for your needs;
- determining your eligibility for our products and services;
- determining eligibility for reimbursement assistance; and
- providing you with information about multiple sclerosis and about our products and services.

## Access and use of information

The personal information you provide will be accessed and used only by Shared Solutions®, our affiliates and authorized agents, and respective staff members, who are required to maintain the confidentiality of your personal information. By agreeing to provide your information in accordance with the terms of this privacy policy, you are giving your consent for us to disclose relevant information from your file to your referring physician, as well as to our affiliates and authorized third parties who assist us in providing services to you (i.e., only the information required for the execution of the service being required from the third party). Such third parties may include, but are not limited to:

- our healthcare professionals (for providing appointment reminders, coordinating appointments, offering advice about or follow-ups on your therapy);
- our service providers (for therapy coverage);
- our mailing house (responsible for sending printed information and publications); or
- potential payers or reimbursement organizations.

You consent to be contacted by Shared Solutions® via phone, text or email and to the transfer of personal information by phone, fax or email between Shared Solutions®, your insurer, and your healthcare provider(s) for the purpose of determining your eligibility for Shared Solutions® and the delivery of Shared Solutions® services. Email and text may be used during the course of your participation in Shared Solutions® to inform you about your status in the Shared Solutions®, provide Shared Solutions® services, and to provide notifications and reminders. You acknowledge that neither email nor text is a secure method of communication. Information in emails and texts has the potential to be accessed and read by a third party. Electronic communication is at your option and you may withdraw this option to communicate electronically at any time. We may share information with external firms, which would be engaged by us to conduct pharmaceutical market research on our behalf, and which may contact you for the sole purpose of gathering market research information. We may also share information with affiliates and health authorities that collect certain information for the purposes of safety monitoring of marketed products, including information, if applicable, relating to the pregnancy of patients enrolled in the Shared Solutions® Patient Support Program.

Furthermore, your information may also be shared with others if explicitly authorized or required by applicable law. Any information which we might have shared with such third parties will be held on a confidential basis and will only be kept by them for as long as it is reasonably needed for the intended purpose of the services they are providing, after which the data in their possession will be securely destroyed.

At no time and under no circumstance will your information be sold to any third party for any reason. The data contained in your file will only be kept for as long as it is reasonably needed, and it will only be used for the purpose stated in your file. Once the purpose has been achieved, your file will be deleted unless you require further services, or unless we are required to maintain a copy under applicable law.

You may choose to withdraw your consent to our access, collection, use, or disclosure of some or all personal information at any time. However, please understand that your decision may prevent us from providing you with services and information that you request.

#### **Protection**

Your information will be stored on a confidential basis at the Shared Solutions® offices and/or secure locations both inside and outside of Canada, including within the European Union, the USA, or in Israel. It is a condition of receiving services from Shared Solutions® that you expressly consent to the secure storage of your personal information outside Canada. It is protected by various physical, technical and administrative security measures such as magnetic locks, data encryption, and a system of individual usernames and passwords for each staff member.

## Contact on behalf of another person

Shared Solutions® must deal directly and exclusively with you; therefore, it is not possible for others to contact Shared Solutions® on your behalf. If you would like a family member, friend, or anyone else to receive services from us, please give him/her our phone number.

## **Keeping your information accurate**

We are committed to keeping your personal information accurate as long as we need it for the purposes previously described. You play an important role in helping us achieve this goal. You may update your information by contacting us either by phone or email. Your prompt notification of any contact information changes will assist us in providing you with the requested services.

## Changes to the privacy policy

Shared Solutions® reserves the right to change, modify, or amend this policy at any time. However, when a significant change has been made, you will be notified within a reasonable time either by phone, mail, or email.

## Shared Solutions® Privacy Officer

1080 Beaver Hall Hill, Suite 1200 Montreal, Quebec H2Z 1S8 TCI.PrivacyOfficer@tevapharm.com

### For more information:

Consult the Product Monograph at https://www.tevacanada.com/globalassets/canada-scs-files---global/our-products-pdfs/0221\_tci\_copaxone\_pm\_en.pdf for contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use. The Product Monograph is also available by calling us at 1 800 283-0034.

Copaxone® and Shared Solutions® and the design versions thereof are registered trademarks of Teva Pharmaceutical Industries Ltd. and are used under license.



ation G.P. – S.E.N.C.,

Patient Support Program

1 800 283-0034

info@sharedsolutions.ca

